Japan's Takeda Pharmaceutical Co Ltd said on Friday that the U.S. Food and Drug Administration approved its lung cancer drug, almost three months after the company acquired the drug's developer, Ariad Pharmaceuticals Inc. The drug, Alunbrig, is approved as a second-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer, who have progressed on or are intolerant to Pfizer's crizotinib, the standard initial treatment for the disease. Alunbrig was approved under the FDA's accelerated approval program, which allows for quicker approval of drugs that fill an unmet medical need.
- PR Newswire•3 days ago
Takeda and Harrington Discovery Institute at University Hospitals Announce a Collaboration to Advance the Development of Rare Disease Therapeutics
OSAKA, Japan and CLEVELAND, April 27, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE:4502), and Harrington Discovery Institute at University Hospitals in Cleveland, Ohio have announced a multi-year collaboration to accelerate breakthrough therapeutic discoveries in rare diseases. A first of a kind partnership for Harrington Discovery Institute with a major pharmaceutical company, this collaboration with Takeda will build on Harrington Discovery Institute's established operating model to create a new program specifically for the advancement of medicines for rare diseases.
TKPYY : Summary for TAKEDA PHARMACEUTI SPON ADR EA - Yahoo Finance
Takeda Pharmaceutical Company Limited (TKPYY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||24.00 - 25.28|
|52 Week Range||19.96 - 25.28|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||32.69|
|Dividend & Yield||0.78 (3.31%)|
|1y Target Est||N/A|